Immunome, Inc. · NASDAQ:IMNM

Immunome — Investor Presentation (April 2021)

38 slides from Immunome's investor presentation, Apr 26, 2021

Slide 1: Harnessing the Human Memory B Cell Response To Develop Antibody-Based Therapeutics
Copyright © 2021 Immunome, Inc. All rights reserved. Harnessing the Human Memory B Cell Response To Develop Antibody - Based Therapeutics April 22, 2021 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | www.immunome.com
Slide 2: Forward Looking Statements
2 Copyright © 2021 Immunome, Inc. All rights reserved. Forward Looking Statements This presentation includes certain disclosures that contain “forward - looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, a
Slide 3: Management Team
Copyright © 2021 Immunome, Inc. All rights reserved. 3 Management Team Michael Morin, PhD Chief Scientific Officer Dennis Giesing , PhD Chief Development Officer Purnanand Sarma, PhD President & CEO Sandra Stoneman, Esq. Chief Legal Officer Corleen Roche Chief Financial Officer Matthew Robinson, PhD
Slide 4: Executive Summary
Copyright © 2021 Immunome, Inc. All rights reserved. 4 Executive Summary Proprietary Discovery Engine • Rapid, unbiased interrogation of memory B cells to identify novel targets and antibodies directed at them • Potential to advance 1 - 2 candidates into IND - enabling studies per year • Broad appli
Slide 5: Immunome Development Pipeline and Anticipated Key Milestones
5 Copyright © 2021 Immunome, Inc. All rights reserved. Immunome Development Pipeline and Anticipated Key Milestones ONCOLOGY TARGET PRODUCT CANDIDATE DESCRIPTION DISCOVERY PRECLINICAL NEXT MILESTONE IMM - ONC - 01 IL - 38 I/O, Novel Checkpoint Anticipate IND filing 2H 2021 ANTI - INFECTIVES TARGET P
Slide 6: The Power of Memory B Cells
Copyright © 2021 Immunome, Inc. All rights reserved. 6 The Power of Memory B Cells Immunome’s Discovery Engine Sees Disease Through the Lens of the Human Memory B Cell • Memory B cells remember specific antigens and allow for a rapid antibody response 1 • The antibodies that these cells produce are
Slide 7: Discovery Engine: Unbiased Interrogation of Memory B Cells
Copyright © 2021 Immunome, Inc. All rights reserved. 7 Discovery Engine Unbiased Interrogation of Memory B Cells Antibody Screening Deep, multiplexed interrogation of patient memory B cell responses Patient Response Capture memory B cells from cancer or infectious disease patients Antibody Validatio
Slide 9: Immunome's Discovery & Output
Copyright © 2021 Immunome, Inc. All rights reserved. 9 Immunome’s Discovery & Output Memory B Cells Interrogation Reveals Target Rich Functional “Clusters” • Common biological processes that may have disease relevance, such as exosome control of the tumor microenvironment 1 - 2 • Novel immune checkp
Slide 10: Immune Response: Uncontrolled vs. Controlled Cancer Environments
Copyright © 2021 Immunome, Inc. All rights reserved. 10 Immune Response Uncontrolled vs. Controlled Cancer Environments Hallmarks of Immune - Controlled Tumors B Cells T Cells Dendritic Cells Macrophages Tertiary Lymphoid Structures in tumor microenvironment Tag exosomes for clearance Target tumor c
Slide 11: B Cell Immunity Offers Access to Multiple Antitumor Mechanisms
Copyright © 2021 Immunome, Inc. All rights reserved. 11 The Power of Memory B Cells B Cell Immunity Offers Access to Multiple Antitumor Mechanisms Tumor - derived Factors/ metastatic cells Target - specific antibodies Tumor of B Cell Donor Responding Patient Immune Modulation Exosomes & Membrane Dyn
Slide 12: Oncology R&D Pipeline
Copyright © 2021 Immunome, Inc. All rights reserved. 12 Oncology R&D Pipeline Mapping the Tumor Through the Lens of the B Cell Identifies Unique Therapeutic Targets Immune Modulators Exosomes & Membrane Dynamics Tumor or Tumor - Associated Stromal Antigens Program Pathways Potential Cancers of Relev
Slide 13: IL-38: A Novel Oncology Target
Copyright © 2021 Immunome, Inc. All rights reserved. 13 IL - 38: A Novel Oncology Target IL - 38 Appears to Dampen Innate Anti - Tumor Immunity • IL - 38 is an IL - 1 cytokine family member, but most closely resembles the natural antagonists of the family (IL - 1Ra and IL - 36a) • IL - 38 inhibits i
Slide 14: IL-38 Expression in Solid Tumors
Copyright © 2021 Immunome, Inc. All rights reserved. 14 IL - 38 Expression in Solid Tumors IL - 38 is Over - Expressed in Multiple Tumors of High Unmet Medical Need, and Associated with Reduced Immune Cell Infiltration IL - 38 is over - expressed in multiple tumors of high unmet medical need Inverse
Slide 15: Clinical Consequences of IL-38 Expression
Copyright © 2021 Immunome, Inc. All rights reserved. 15 Clinical Consequences of IL - 38 Expression Recent Literature Reports Show Correlation Between IL - 38 and Tumor Growth IL - 38 high IL - 38 low
Slide 16: IL-38 & Innate Immunity
Copyright © 2021 Immunome, Inc. All rights reserved. 16 IL - 38 & Innate Immunity IL - 38 Inhibits Myeloid Cell Activation In Vitro Blocks IL - 36 mediated inflammatory signals IL - 36 γ induced IL - 8 in PBMCs PNAS 2012;109 (8):3001 Suppresses Dendritic Cell Function Inhibits macrophage inflammator
Slide 17: IMM-ONC-01 Blocking IL-38 Leads to Tumor Control in Two Tumor Models
Copyright © 2021 Immunome, Inc. All rights reserved. 17 IMM - ONC - 01 Blocking IL - 38 Leads to Tumor Control in Two Different Tumor Models Demonstration of Anti - Tumor Activity (B16F10 Model) Induction of Anti - Tumor Memory (EMT6 Model) • Immunologically cold tumor model • IMM - ONC - 01 equival
Slide 18: IMM-ONC-01 Program Summary
Copyright © 2021 Immunome, Inc. All rights reserved. 18 IMM - ONC - 01 Program Summary Modulating Innate Anti - Tumor Immunity • IL - 38 is a novel checkpoint in the innate immune system » Target of an antibody isolated from the memory B cells of a patient with head and neck cancer • Targeting IL -
Slide 20: IMM-BCP-01: Therapeutic Antibody Cocktail Against Multiple SARS-CoV-2 Antigens
Copyright © 2021 Immunome, Inc. All rights reserved. 20 IMM - BCP - 01 Therapeutic Antibody Cocktail Against Multiple SARS - CoV - 2 Antigens Collaboration with U.S. DoD awarded, up to $13.3M in funding Select convalescent patients with strong anti - viral titer Antibody cocktail for potential proph
Slide 21: SARS-CoV-2 Evolving Landscape
Copyright © 2021 Immunome, Inc. All rights reserved. 21 SARS - CoV - 2 Evolving Landscape SARS - CoV - 2 Variants Driving Need for Novel Therapies SARS - CoV - 2 Emerging Escape Mutants • Certain variants exhibit increased transmission and decrease the efficacy of vaccines & therapeutics • UK (B.1.1
Slide 22: IMM-BCP-01 Highlights
Copyright © 2021 Immunome, Inc. All rights reserved. 22 IMM - BCP - 01 Highlights • Antibody cocktail (IMM - BCP - 01) is a combination of three antibodies that bind to complementary, non - overlapping regions of the SARS - CoV - 2 spike protein. • Neutralizes South Africa (B.1.351) and UK (B.1.1.7)
Slide 23: IMM-BCP-01 Antibody Cocktail: Triangulating the Spike Protein
Copyright © 2021 Immunome, Inc. All rights reserved. 23 IMM - BCP - 01 Antibody Cocktail Triangulating the Spike Protein: Targeting Three Non - Overlapping Regions x Antibody A : binds to ACE2 binding site, highly potent neutralizer x Antibody B : binds to an epitope conserved in all CoV - 2 variant
Slide 24: IMM-BCP-01 Cocktail Approach Translates to Efficacy Across Multiple Variants
Copyright © 2021 Immunome, Inc. All rights reserved. 24 IMM - BCP - 01 Cocktail Approach Translates to Efficacy Across Multiple Variants in Pre - clinical Testing • Pseudovirus neutralization across multiple strains • CDC - SARS - CoV - 2 Variants of Concern (04/14/21 ): Brazilian (P.1), Californian
Slide 25: IMM-BCP-01 Exhibits Robust Activity In Vitro and In Vivo
Copyright © 2021 Immunome, Inc. All rights reserved. 25 IMM - BCP - 01 Exhibits Robust Activity In Vitro and In Vivo – Select Examples Antibody Cocktail Neutralizes UK (B.1.1.7) Antibody Cocktail Reduces Viral Lung Titer • IMM - BCP - 01 live virus neutralization in vitro • IMM - BCP - 01 treatment
Slide 26: IMM-BCP-01 Program
Copyright © 2021 Immunome, Inc. All rights reserved. 26 IMM - BCP - 01 Program Antibody Cocktail With Activity Against Multiple Emerging SARS - CoV - 2 Variants in Pre - clinical Testing x Binding to three non - overlapping regions of RBD, leading to combinatorial activity x Neutralize multiple SARS
Slide 28: Immunome Pipeline & Anticipated Milestones
28 Copyright © 2021 Immunome, Inc. All rights reserved. ONCOLOGY TARGET PRODUCT CANDIDATE DESCRIPTION DISCOVERY PRECLINICAL NEXT MILESTONE IMM - ONC - 01 IL - 38 I/O, Novel Checkpoint Anticipate IND filing 2H 2021 ANTI - INFECTIVES TARGET PRODUCT CANDIDATE DESCRIPTION DISCOVERY PRECLINICAL NEXT MILE
Slide 29: Finance and Intellectual Property
Copyright © 2021 Immunome, Inc. All rights reserved. 29 Finance and Intellectual Property Intellectual Property » Broad patent estate covering technology and applications » Exclusively licensed patents covering platform from key academic institutions » Significant additional platform intellectual pr
Slide 30: Executive Summary
Copyright © 2021 Immunome, Inc. All rights reserved. 30 Executive Summary Proprietary Discovery Engine • Rapid, unbiased interrogation of memory B cells to identify novel targets and antibodies directed at them • Potential to advance 1 - 2 candidates into IND - enabling studies per year • Broad appl
Slide 32: Scientific Advisory Board
Copyright © 2021 Immunome, Inc. All rights reserved. 32 Scientific Advisory Board Scott Dessain, MD, PhD Chair, Founder Joseph and Ray Gordon Chair of Clinical Oncology and Research at Lankenau Institute for Medical Research George Prendergast, PhD Cancer Biology Former Editor of Cancer Research Pre
Slide 33: Board of Directors
Copyright © 2021 Immunome, Inc. All rights reserved. 33 Board of Directors Michael Rapp, Chairman Managing Partner, Broadband Capital Investments, LLC Richard Baron Formerly Chief Financial Officer, Zynerba Pharmaceuticals John LaMattina, PhD Formerly President, Pfizer Global Research & Development
Slide 34: Using the B Cell Lens: Discovery Engine Appears to Reveal Rare and Novel Targets
Copyright © 2021 Immunome, Inc. All rights reserved. 34 Using the B Cell Lens Discovery Engine Appears to Reveal Rare and Novel Targets • Rare, broadly conserved epitopes in infectious disease » Antibodies binding to Spike protein epitopes conserved across multiple SARS - CoV - 2 variants and even S
Slide 35: IMM-BCP-01 Hypothesis: Neutralizing Antibody Therapeutics vs. Antibody Cocktail
Copyright © 2021 Immunome, Inc. All rights reserved. 35 IMM - BCP - 01 Hypothesis Neutralizing Antibody Therapeutics vs. Immunome’s Antibody Cocktail Approach Neutralizing Antibodies • Target single protein • New strains may readily evade IMM - BCP - 01 Profile ▪ Multiple antibodies against diverse
Slide 36: B Cell Interrogation of Super-Responders
Copyright © 2021 Immunome, Inc. All rights reserved. 36 B Cell Interrogation of Super - Responders “Super Responders” Mount Robust Immune Response Against SARS - CoV - 2 More than 50% of the antibodies identified bind to SARS - CoV - 2 proteins other than Spike • Open Reading Frame - coded (ORF) pro
Slide 37: Untapped Potential in Immuno-Oncology
Copyright © 2021 Immunome, Inc. All rights reserved. 37 Untapped Potential in Immuno - Oncology Current Therapies are Based on Limited Understanding of the Diversity and Complexity of Human Tumors T cell targeted immuno - oncology approaches have redefined the way we treat cancer However, large numb
Slide 38: Memory B Cells and Cancer
Copyright © 2021 Immunome, Inc. All rights reserved. 38 Memory B Cells and Cancer Memory B - Cells Play a Powerful Role in the Immune Response to Cancer B cells are a key feature of successful anti - cancer immunity » B cells secrete cytokines, present antigens, and generate antibodies » The presenc

Immunome — Investor Presentation (April 2021) on 6ix

Immunome — Investor Presentation (April 2021)

Slide 1: Harnessing the Human Memory B Cell Response To Develop Antibody-Based Therapeutics

Slide 2: Forward Looking Statements

Slide 3: Management Team

Slide 4: Executive Summary

Slide 5: Immunome Development Pipeline and Anticipated Key Milestones

Slide 6: The Power of Memory B Cells

Slide 7: Discovery Engine: Unbiased Interrogation of Memory B Cells

Slide 8: Oncology Research & Development

Slide 9: Immunome's Discovery & Output

Slide 10: Immune Response: Uncontrolled vs. Controlled Cancer Environments

Slide 11: B Cell Immunity Offers Access to Multiple Antitumor Mechanisms

Slide 12: Oncology R&D Pipeline

Slide 13: IL-38: A Novel Oncology Target

Slide 14: IL-38 Expression in Solid Tumors

Slide 15: Clinical Consequences of IL-38 Expression

Slide 16: IL-38 & Innate Immunity

Slide 17: IMM-ONC-01 Blocking IL-38 Leads to Tumor Control in Two Tumor Models

Slide 18: IMM-ONC-01 Program Summary

Slide 19: Infectious Diseases Research & Development

Slide 20: IMM-BCP-01: Therapeutic Antibody Cocktail Against Multiple SARS-CoV-2 Antigens

Slide 21: SARS-CoV-2 Evolving Landscape

Slide 22: IMM-BCP-01 Highlights

Slide 23: IMM-BCP-01 Antibody Cocktail: Triangulating the Spike Protein

Slide 24: IMM-BCP-01 Cocktail Approach Translates to Efficacy Across Multiple Variants

Slide 25: IMM-BCP-01 Exhibits Robust Activity In Vitro and In Vivo

Slide 26: IMM-BCP-01 Program

Slide 27: Summary

Slide 28: Immunome Pipeline & Anticipated Milestones

Slide 29: Finance and Intellectual Property

Slide 30: Executive Summary

Slide 31: Appendix

Slide 32: Scientific Advisory Board

Slide 33: Board of Directors

Slide 34: Using the B Cell Lens: Discovery Engine Appears to Reveal Rare and Novel Targets

Slide 35: IMM-BCP-01 Hypothesis: Neutralizing Antibody Therapeutics vs. Antibody Cocktail

Slide 36: B Cell Interrogation of Super-Responders

Slide 37: Untapped Potential in Immuno-Oncology

Slide 38: Memory B Cells and Cancer